Quantum Genomics has granted an exclusive license to Biolab Sanus Pharmaceutical to develop and commercialize…
News
Quantum Genomics Reports First Half 2019 Financial Results and Provides Corporate Update
The financial statements for the first half of 2019 reflect operating results of -€5.3 million,…
Quantum Genomics Launches Study of Firibastat in Patients with Renal Failure
“The analysis of NEW-HOPE, Quantum Genomics’ Phase IIb study of firibastat in hypertension, has demonstrated…
Quantum Genomics Announces Positive FDA Feedback on Phase III Program Design of Firibastat in Resistant Arterial Hypertension
“Currently, 150 million people around the globe struggle with difficult-to-control or treatment-resistant arterial hypertension, and…
2017/06/07 – Quantum Genomics to host two upcoming events
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing…
2017/05/23 – Quantum Genomics to Host Key Opinion Leader Event Focused on Phase IIa Hypertension Data and the Upcoming Clinical Trial in the United States
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2017/05/09 – Quantum Genomics will organize a teleconference on June 19, 2017, to comment on phase IIa data in high blood pressure
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2017/04/25 – Quantum Genomics appoints Bruno Besse as Chief Medical Officer
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2017/03/30 – 2016 annual financial results and next development steps in 2017
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2017/03/14 – Quantum Genomics announces positive data from new preclinical studies with QGC001
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…